Standard BioTools Inc. Increase (Decrease) in Deferred Compensation
Standard BioTools Inc. (LAB) reported Increase (Decrease) in Deferred Compensation of $3.02 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCompensation · last filed 2024-03-01
- Standard BioTools Inc. increase (decrease) in deferred compensation for the quarter ending 2023-12-31 was $1.65M.
- Standard BioTools Inc. increase (decrease) in deferred compensation for the quarter ending 2023-09-30 was $707.00K, a 63.98% decline year-over-year.
- Standard BioTools Inc. increase (decrease) in deferred compensation for the quarter ending 2023-06-30 was $1.41M, a 151.87% increase year-over-year.
- Standard BioTools Inc. increase (decrease) in deferred compensation for the quarter ending 2023-03-31 was -$754.00K, a 124.83% decline year-over-year.
- Standard BioTools Inc. increase (decrease) in deferred compensation for fiscal 2023 was $3.02M, a 26.62% decline from fiscal 2022.
- Standard BioTools Inc. increase (decrease) in deferred compensation for fiscal 2022 was $4.11M.
- Standard BioTools Inc. increase (decrease) in deferred compensation for fiscal 2021 was -$8.72M, a 201.09% decline from fiscal 2020.
- Standard BioTools Inc. increase (decrease) in deferred compensation for fiscal 2020 was $8.63M.
| Period end | Increase (Decrease) in Deferred Compensation 3 month | Increase (Decrease) in Deferred Compensation 6 month | Increase (Decrease) in Deferred Compensation 9 month | Increase (Decrease) in Deferred Compensation 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.36M derived: sum of 2 quarters · filed 2024-03-01 | $3.77M derived: sum of 3 quarters · filed 2024-03-01 | $3.02M 10-K · filed 2024-03-01 |
| 2023-09-30 | $707.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.12M derived: sum of 2 quarters · filed 2023-11-07 | $1.37M 10-Q · filed 2023-11-07 | -$82.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $659.00K 10-Q · filed 2023-08-08 | -$789.00K derived: sum of 3 quarters · filed 2024-03-01 | $1.17M derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | -$754.00K 10-Q · filed 2023-05-09 | -$2.20M derived: sum of 2 quarters · filed 2024-03-01 | -$239.00K derived: sum of 3 quarters · filed 2024-03-01 | $322.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $515.00K derived: sum of 2 quarters · filed 2024-03-01 | $1.08M derived: sum of 3 quarters · filed 2024-03-01 | $4.11M 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.52M derived: sum of 2 quarters · filed 2023-11-07 | $5.56M 10-Q · filed 2023-11-07 | $2.23M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $561.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.60M 10-Q · filed 2023-08-08 | $271.00K derived: sum of 3 quarters · filed 2023-08-08 | $236.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $3.04M 10-Q · filed 2023-05-09 | -$290.00K derived: sum of 2 quarters · filed 2023-05-09 | -$325.00K derived: sum of 3 quarters · filed 2023-05-09 | -$664.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$3.36M derived: sum of 2 quarters · filed 2023-03-14 | -$3.70M derived: sum of 3 quarters · filed 2023-03-14 | -$8.72M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$374.00K derived: sum of 2 quarters · filed 2022-11-09 | -$5.39M 10-Q · filed 2022-11-09 | -$762.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$5.36M 10-Q · filed 2022-08-09 | -$727.00K derived: sum of 3 quarters · filed 2022-08-09 | $1.77M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$5.02M 10-Q · filed 2022-05-09 | -$388.00K derived: sum of 2 quarters · filed 2022-05-09 | $2.11M derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $7.13M derived: sum of 2 quarters · filed 2022-03-08 | $8.63M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $4.00M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $1.50M 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | -$9.31M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |